PharmiWeb5d
Libtayo® (cemiplimab) Now Available on the National Health Service in Scotland for Patients with Recurrent or Metastatic Cervical Cancer
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...
pharmaphorum1d
Sanofi gets first OK for isatuximab for myeloma, challenging J&J’s Darzalex
Sarclisa was developed in collaboration with ImmunoGen and according to Sanofi has a simpler infusion regimen than ... for its cancer business along with Libtayo (cemiplimab), a PD-1 inhibitor ...
pharmaphorum3d
MSD, Moderna take mRNA jab into phase 3 for lung cancer
Patients in the study will receive a 1 mg dose of V940 via intramuscular (IM) injection or a matched placebo once every three weeks for up to nine doses, along with an infusion of Keytruda once ...
Cure Today5d
THIO and Libtayo Extends OS in NSCLC Following Progression on SOC Therapy
The trial evaluates THIO's safety, tolerability, and efficacy in combination with PD-(L)1 inhibition. THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who ...
PharmaTimes4d
Libtayo available in Scotland for cervical cancer patients
Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for use on the National Health Service. This approval is for second-line monotherapy ...
Managed Healthcare Executive5d
AI Model Shows Promise in Reducing Skin Cancer Detection Bias
A novel AI model was able to achieve 99.86% accuracy for diagnosing skin conditions, even in people with darker skin tones or excessive hair. A new artificial intelligence (AI) model designed to ...